The 3rd Schizophrenia International Research Society Conference, 14-18 April 2012, Florence, Italy: Summaries of oral sessions

Schizophrenia Research

Volumn 141, Issue 1, 2012, Pages

  Abbs, Brandon ^a   Achalia, Rashmin M ^b   Adelufosi, Adegoke O ^c   Aktener, Ahmet Yiǧit ^d   Beveridge, Natalie J ^e   Bhakta, Savita G ^f   Blackman, Rachael K ^g   Bora, Emre ^h   Byun, M S ⁱ   Cabanis, Maurice ^j   Carrion, Ricardo ^f,k   Castellani, Christina A ^l   Chow, Tze Jen ^m   Dmitrzak Weglarz, M ⁿ   Gayer Anderson, Charlotte ^o   Gomes, Felipe V ^p   Haut, Kristen ^q   Hori, Hiroaki ^r   Kantrowitz, Joshua T ^s   Kishimoto, Taishiro ^f,t   Lee, Frankie H F ^u,v   Lin, Ashleigh ^w   Palaniyappan, Lena ^x   Quan, Meina ^a,y   Rubio, Maria D ^z   de Azúa, Sonia Ruiz ^aa   Sahoo, Saddichha ^ab   Strauss, Gregory P ^ac   Szczepankiewicz, Aleksandra ⁿ   Thompson, Andrew D ^ad   Trotta, Antonella ^o   Tully, Laura M ^ae   Uchida, Hiroyuki ^t   Velthorst, Eva ^af   Young, Jared W ^ag   O'Shea, Anne ^ah   DeLisi, Lynn E ^y   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b GOVERNMENT MEDICAL COLLEGE   (India)

^c Ladoke Akintola University Teaching Hospital   (Nigeria)

^d Kahramanmara Göksun State Hospital   (Turkey)

^e UNIVERSITY OF NEWCASTLE   (Australia)

^f ZUCKER HILLSIDE HOSPITAL   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ Seoul National University College of Medicine   (South Korea)

^j PHILIPPS UNIVERSITY MARBURG   (Germany)

^k FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^l UNIVERSITY OF WESTERN ONTARIO   (Canada)

^m UNIVERSITI TUNKU ABDUL RAHMAN   (Malaysia)

ⁿ POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^o KING'S COLLEGE LONDON   (United Kingdom)

^p UNIVERSITY OF SÃO PAULO   (Brazil)

^q UNIVERSITY OF CALIFORNIA   (United States)

^r NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^s NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^t KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^u CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^v UNIVERSITY OF TORONTO   (Canada)

^w UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^x UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^y HARVARD MEDICAL SCHOOL   (United States)

^z UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^aa UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^ab UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^ac MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^ad THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^ae HARVARD UNIVERSITY   (United States)

^af ACADEMIC MEDICAL CENTER   (Netherlands)

^ag UNIVERSITY OF CALIFORNIA   (United States)

^ah VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

Brain imaging; Conference; Gene environment interaction; Genetics; Schizophrenia; Treatment

Indexed keywords

DOPAMINE 2 RECEPTOR;

ARTICLE; BIPOLAR DISORDER; CANNABIS ADDICTION; CELL MIGRATION; CLINICAL FEATURE; COGNITION; ENVIRONMENTAL FACTOR; EUROPE; GENE SEQUENCE; GENOTYPE ENVIRONMENT INTERACTION; HOMICIDE; HUMAN; IMMIGRANT; INFLAMMATION; INTELLIGENCE; ITALY; MEDICAL RESEARCH; MEDICAL SOCIETY; MOOD DISORDER; NERVE CELL DIFFERENTIATION; NEUROIMAGING; NEUROPSYCHOLOGY; NONHUMAN; OXIDATIVE STRESS; PATERNAL AGE; PRIORITY JOURNAL; PROTEIN FOLDING; PSYCHOSIS; RISK FACTOR; SCHIZOPHRENIA; SEX DIFFERENCE;

CONGRESSES AS TOPIC; HUMANS; INTERNATIONAL AGENCIES; ITALY; SCHIZOPHRENIA; SOCIETIES, MEDICAL;

EID: 84865998569     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.07.024     Document Type: Article

References (164)

1. Abazyan B., Nomura J., Kannan G., et al. Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biol. Psychiatry 2010, 68(12):1172-1181.
2. Abubaker R., Alaerts M., Allman A.A., et al. Summary of the 1st Schizophrenia International Research Society Conference oral sessions, Venice, Italy, June 21-25, 2008: the rapporteur reports. Schizophr. Res. 2009, 107(2-3):337. Feb.
3. Adcock R.A., Dale C., Fisher M., et al. When top-down meets bottom-up: auditory training enhances verbal memory in schizophrenia. Schizophr. Bull. 2009, 35(6):1132-1141.
4. Addington J., Cadenhead K.S., Cannon T.D., et al. North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr. Bull. 2007, 33(3):665-672.
5. Agnew-Blais, J., Seidman, L.J., in press. Neurocognition in youth and young adults under age 30 at familial risk for schizophrenia. Psychol Med.
6. AGREE collaboration Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual. Saf. Health Care 2003, 12(18-23).
7. Amminger G.P., McGorry P.D. Update on omega-3 polyunsaturated fatty acids in early-stage psychotic disorders. Neuropsychopharmacology 2012, 37(1):309-310.
8. Amminger G.P., Schäfer M.R., Papageorgiou K., et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67(2):146-154.
9. Armando, M., Girardi, P., Lin, A., et al., submitted for publication. Prevalence of psychotic-like experiences in young adults with social anxiety disorder and correlation with affective dysregulation associative regions of the striatum in schizophrenia. Arch Gen Psychiatry. 67(3):231-239.
10. Baharnoori M., Bartholomeusz C., Boucher A.A., et al. The 2nd Schizophrenia International Research Society Conference, 10-14 April 2010, Florence, Italy: summaries of oral sessions. Schizophr. Res. 2010, 10.1016/j.schres.2010.09.008.
11. Barkus E., Morrison P.D., Vuletic D., et al. Does intravenous Delta9-tetrahydrocannabinol increase dopamine release? A SPET study. J. Psychopharmacol. 2011, 25(11):1462-1468.
12. Bertani M., Lasalvia A., Bonetto C., et al. The influence of gender on clinical and social characteristics of patients at psychosis onset: a report from the Psychosis Incident Cohort Outcome Study (PICOS). Psychol. Med. 2012, 42(4):769-780.
13. Bhattacharyya S., Crippa J.A., Allen P. Induction of psychosis by {delta}9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch. Gen. Psychiatry 2012, 69(1):27-36.
14. Bossong M.G., van Berckel B.N., Boellaard R., et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009, 34(3):759-766.
15. Brown A.S. Prenatal infection as a risk factor for schizophrenia. Schizophr. Bull. 2006, 32(2):200-202.
16. Brown A.S. Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism. Dev. Neurobiol. 2012, (Apr 5 Epub ahead of print). 10.1002/dneu.22024.
17. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am. J. Psychiatry 2010, 167(3):261-280.
18. Brown A.S., Begg M.D., Gravenstein S., et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch. Gen. Psychiatry 2004, 61(8):774-780.
19. Cascella N.G., Kryszak D., Bhatti B., et al. Prevalence of celiac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population. Schizophr. Bull. 2011, 37(1):94-100.
20. Cascella N.G., Santora D., Gregory P., et al. Increased prevalence of transglutaminase 6 antibodies in sera from schizophrenia patients. Schizophr. Bull. 2012, 10.1093/schbul/sbs064.
21. Cheer J.F., Wassum K.M., Heien M.L., et al. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J. Neurosci. 2004, 24(18):4393-4400.
22. Chen K.C., Yang Y.K., Howes O., et al. Striatal dopamine transporter availability in drug-naive patients with schizophrenia: a case-control SPECT study with [99mTc]-TRODAT-1 and a meta-analysis. Schizophr. Bull. 2011, (Dec 8).
23. Cohen A.N., Hamilton A.B., Saks E., et al. Lessons from high achieving individuals with schizophrenia. Mindview 2011, 4(4):1-2.
24. Cooper J.C., Knutson B. Valence and salience contribute to nucleus accumbens activation. Neuroimage 2008, 39(1):538-547.
25. Cotman C.W., Berchtold N.C. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci. 2002, 25(6):295-301.
26. Daalman, K., Diederen, K.M.J., Derks, E.M., et al., 2012. Childhood trauma and auditory verbal hallucinations. Psychol. Med. FirstView, 1-10.
27. Dauvermann M., Mukherjee P., Moorhead W., et al. Relationship between gyrification and functional connectivity of the prefrontal cortex in subjects at high genetic risk of schizophrenia. Curr. Pharm. Des. 2012, 18(4):434-442.
28. De Hert M., Dekker J.M., Wood D., et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur. Psychiatry 2009, 24:412-424.
29. Demontis D., Nyegaard M., Buttenschon H.N., et al. Association of GRIN1 and GRIN2A-D with schizophrenia and genetic interaction with maternal herpes simplex virus-2 infection affecting disease risk. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2011, 156B(8):913-922.
30. Dickerson F., Lillehoj E., Stallings C., Wiley M., Origoni A., Vaughan C., Khushalani S., Sabunciyan S., Yolken R. Antibodies to retroviruses in recent onset psychosis and multi-episode schizophrenia. Schizophr. Res. 2012, 138(2-3):198-205.
31. Diederen, K.M.J., Daalman, K., de Weijer, A.D., et al., in press. Auditory hallucinations elicit similar brain activation in psychotic and nonpsychotic individuals. Schizophr Bull. http://dx.doi.org/10.1093/schbul/sbr033.
32. Drexhage R.C., Knijff E.M., Padmos R.C., et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev. Neurother. 2010, 10(1):59-76.
33. Eaton W.W., Pedersen M.G., Nielsen P.R., Mortensen P.B. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord. 2010, 12(6):638-646.
34. Ellman L.M., Deicken R.F., Vinogradov S., et al. Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. Schizophr. Res. 2010, 121(1-3):46-54.
35. Fearon P., Kirkbride J.B., Morgan C., et al. Incidence of schizophrenia and other psychoses in ethnic minority groups: results from the MRC AESOP study. Psychol. Med. 2006, 36(11):1541-1550.
36. Findling R.L., Cavus I., Pappadolulos E., et al. A placebo-controlled trial to evaluate the efficacy and safety of flexibly dosed oral ziprasidone in adolescent subjects with schizophrenia. Schizophr. Res. 2010, 117(2-3):437.
37. Frans E.M., Sandin S., Reichenberg A., et al. Advancing paternal age and bipolar disorder. Arch. Gen. Psychiatry 2008, 65(9):1034-1040.
38. Frans E.M., McGrath J.J., Sandin S., et al. Advanced paternal and grandpaternal age and schizophrenia: a three-generation perspective. Schizophr. Res. 2011, 133:120-124.
39. Fusar-Poli P., Crippa J.A., Bhattacharyya S., et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch. Gen. Psychiatry 2009, 66(1):95-105.
40. Gaebel W., Schreiner A., Bergmans P., et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology 2010, 35(12):2367-2377.
41. Gajwani, R., Patterson, P., Birchwood, M., submitted for publication. Attachment: developmental pathways to affective disregulation in young people at ultra-high-risk of developing psychosis.
42. Garety P.A., Kuipers E., Fowler D., et al. A cognitive model of the positive symptoms of psychosis. Psychol. Med. 2001, 31(2):189-195.
43. Garety P.A., Bebbington P., Fowler D., et al. Implications for neurobiological research of cognitive models of psychosis: a theoretical paper. Psychol. Med. 2007, 37(10):1377-1391.
44. Garety P.A., Fowler D.G., Freeman D., et al. Cognitive-behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: randomised controlled trial. Br. J. Psychiatry 2008, 192(6):412-423.
45. Giuliano A.J., Li H., Mesholam-Gately R.I., et al. Neurocognition in the psychosis risk syndrome: a quantitative and qualitative review. Curr. Pharm. Des. 2012, 18(4):399-415.
46. Goff D.C., Cather C., Gottlieb J.D., et al. Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr. Res. 2008, 106(2-3):320-327.
47. Gold J.M., Hahn B., Strauss G.P., et al. Turning it upside down: areas of preserved cognitive function in schizophrenia. Neuropsychol. Rev. 2009, 19(3):294-311.
48. Goriely A., Wilkie A.O. Paternal age effect mutations and selfish spermatogonial selection: causes and consequences for human disease. Am. J. Hum. Genet. 2012, 90:175-200.
49. Goriely A., McVean G.A., Röjmyr M., et al. Evidence for selective advantage of pathogenic FGFR2 mutations in the male germ line. Science 2003, 301:643-646.
50. Goriely A., Hansen R.M., Taylor I.B., et al. Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumours. Nat. Genet. 2009, 41(11):1247-1252.
51. Gottlieb J.D., Cather C., Shanahan M., et al. d-Cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Schizophr. Res. 2011, 131(1-3):69-74.
52. Graff-Guerrero A., Redden L., Abi-Saab W., et al. Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int. J. Neuropsychopharmacol. 2010, 13(3):273-287.
53. Hafner H., an der Heiden W., Behrens S., et al. Causes and consequences of the gender difference in age at onset of schizophrenia. Schizophr. Bull. 1998, 24(1):99-113.
54. Hill M., Shannahan K., Jasinski S., et al. Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr. Res. 2011, 127(1-3):41-45.
55. Hill M., Shannahan K., Jasinski S., Macklin E.A., et al. Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr. Res. 2011, 127(41-45).
56. Hoffman R.E., Hawkins K.A., Gueorguieva R., et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations. Arch. Gen. Psychiatry 2003, 60(1):49-56.
57. Holt D.J., Lebron-Milad K., Milad M.R., et al. Extinction memory is impaired in schizophrenia. Biol. Psychiatry 2009, 65:455-463.
58. Horan W.P., Kern R.S., Tripp C., et al. Efficacy and specificity of social cognitive skills training for outpatients with psychotic disorders. J. Psychiatr. Res. 2011, 45:1113-11122.
59. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr. Bull. 2009, 35:549-562.
60. Howes O., Bose S., Turkheimer F., et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol. Psychiatry 2011, 16(9):885-886.
61. Howes, O.D., Shotbolt, P., Bloomfield, M., et al., in press. Dopaminergic function in the psychosis spectrum: an [18F]-DOPA imaging study in healthy individuals with auditory hallucinations. Schizophr Bull. http://dx.doi.org/10.1093/schbul/sbr195.
62. Izzo A.A., Borrelli F., Capasso R., et al. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci. 2009, 30(10):515-527.
63. Kamiya A., Sedlak T.W., Pletnikov M.V. DISC1 pathway in brain development: exploring therapeutic targets for major psychiatric disorders. Front Psychiatry 2012, 3:25.
64. Kegeles L.S., Abi-Dargham A., Frankle W.G., et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch. Gen. Psychiatry 2010, 67(3):231-239.
65. Keks N.A., Ingham M., Khan A., Karcher K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br. J. Psychiatry 2007, 191:131-139.
66. Kelleher I., Keeley H., Corcoran P., Lynch F., Fitzpatrick C., Devlin N., et al. Clinicopathological significance of psychotic experiences in non-psychotic young people: evidence from four population-based studies. The British Journal of Psychiatry 2012, 201(1):26-32.
67. Kellendonk C., Simpson E.H., Polan H.J., et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006, 49(4):603-615.
68. Kemp A.S., Schooler N.R., Kalali A.H., et al. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?. Schizophr. Bull. 2010, 36(3):504-509.
69. Keri S., Kiss I., Seres I., Kelemen O. A polymorphism of the neuregulin 1 gene (SNP8NRG243177/rs6994992) affects reactivity to expressed emotion in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009, 150B(3):418-420.
70. Khandaker G.M., Barnett J.H., White I.R., et al. A quantitative meta-analysis of populationbased studies of premorbid intelligence and schizophrenia. Schizophr. Res. 2011, 132(2-3):220-227.
71. Kinon B.J., Zhang L., Millen B.A., et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J. Clin. Psychopharmacol. 2011, 31(3):349-355.
72. Kirkbride J.B., Errazuriz A., Croudace T.J., et al. Incidence of schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analyses. PLoS One 2012, 7(3):e31660.
73. Kishimoto T., Agarwal V., Kishi T., et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol. Psychiatry 2011, Nov 29. 10.1038/mp.2011.143.
74. Konings M., Stefanis N., Kuepper R., et al. Replication in two independent population-based samples that childhood maltreatment and cannabis use synergistically impact on psychosis risk. Pyschol. Med. 2012, 42(1):149-159.
75. Koutsouleris N., Meisenzahl E.M., Davatzikos C., et al. Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. Arch. Gen. Psychiatry 2009, 66(7):700-712.
76. Koutsouleris, N., Borgwardt, S., Meisenzahl, E.M., et al., in press. Disease prediction in the at-risk mental state for psychosis using neuroanatomical biomarkers: Results from the FePsy study. Schizophr. Bull. http://dx.doi.org/10.1093/schbul/sbr145.
77. Kuepper R., van Os J., Lieb R., et al. Do cannabis and urbanicity co-participate in causing psychosis? Evidence from a 10-year follow-up cohort study. Psychol. Med. 2011, 41(10):2121-2129.
78. Kuipers E., Garety P., Fowler D., et al. Cognitive, emotional, and social processes in psychosis: refining cognitive behavioral therapy for persistent positive symptoms. Schizophr. Bull. 2006, 32(Suppl. 1):S24-S31.
79. Kumari V., Peters E.R., Fannon D., et al. Dorsolateral prefrontal cortex activity predicts responsiveness to cognitive-behavioral therapy in schizophrenia. Biol. Psychiatry 2009, 66(6):594-602.
80. Kumra S., Kranzler H., Gerbino-Rosen G., et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol. Psychiatry 2008, 63(5):524-529.
81. Kurtz M.M., Mueser K.T. A meta-analysis of controlled research on social skills training for schizophrenia. J. Consult. Clin. Psychol. 2008, 76(3):491-504.
82. Kyaga S., Lichtenstein P., Boman M., et al. Creativity and mental disorder: family study of 300,000 people with severe mental disorder. Br. J. Psychiatry 2011, 199(5):373-379.
83. Large M., Smith G., Nielssen O. The relationship between the rate of homicide by those with schizophrenia and the overall homicide rate: a systematic review and meta-analysis. Schizophr. Res. 2009, 112(1):123-129.
84. Larsen T.K., McGlashan T.H., Moe L.C. First-episode schizophrenia: I. Early course parameters. Schizophr. Bull. 1996, 22(2):241-256.
85. Laruelle M., Abi-Dargham A., van Dyck C.H., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(17):9235-9240.
86. Laurens K.R., Hodgins S., Maughan B., et al. Community screening for psychotic-like experiences and other putative antecedents of schizophrenia in children aged 9-12 years. Schizophr. Res. 2007, 90(1):130-146.
87. Laurens, K.R., Hobbs, M.J., Sunderland, M., et al., 2012. Psychotic-like experiences in a community sample of 8000 children aged 9 to 11 years: an item response theory analysis. Psychol. Med. 42 (7), 1495-1506.
88. Lederbogen F., Kirsch P., Haddad L., et al. City living and urban upbringing affect neural social stress processing in humans. Nature 2011, 474(7352):498-501.
89. Lee H., Malaspina D., Ahn H., et al. Paternal age related schizophrenia (PARS): latent subgroups detected by k-means clustering analysis. Schizophr. Res. 2011, 128:143-149.
90. Lencz T., Robinson D.G., Xu K., et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am. J. Psychiatry 2006, 163(3):529-531.
91. Leucht S., Komossa K., Rummel-Kluge C., et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry 2009, 166(2):152-163.
92. Leweke F.M., Piomelli D., Pahlisch F., et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Trans. Psychiatry 2012, 2:e94.
93. Lin A., Wigman J., Nelson B., et al. The relationship between coping and subclinical psychotic experiences in adolescents from the general population-a longitudinal study. Psychol. Med. 2011, 1(1):1-12.
94. Linscott R.J., van Os J. Systematic reviews of categorical versus continuum models in psychosis: evidence for discontinuous subpopulations underlying a psychometric continuum. Implications for DSM-V, DSM-VI, and DSM-VII. Annu. Rev. Clin. Psychol. 2010, 6:391-419.
95. Lodge D.J., Grace A.A. Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia. Neurotox. Res. 2008, 14(2-3):97-104.
96. Malhotra A.K., Buchanan R.W., Kim S. Allelic variation in the promotor region of the dopamine D2 receptor gene and clozapine response. Schizophr. Res. 1996, 36:92-93.
97. Martinez D., Broft A., Foltin R.W., et al. Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior. Neuropsychopharmacology 2004, 29(6):1190-1202.
98. Martinez D., Gil R., Slifstein M., et al. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol. Psychiatry 2005, 58(10):779-786.
99. Mattai A., Chavez A., Greenstein D., et al. Effects of clozapine and olanzapine on cortical thickness in childhood-onset schizophrenia. Schizophr. Res. 2010, 116(1):44-48.
100. McOmish C.E., Burrows E., Howard M., et al. Phospholipase C-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration. Mol. Psychiatry 2008, 13:661-672.
101. Meyer-Lindenberg A., Miletich R.S., Kohn P.D., et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci. 2002, 5(3):267-271.
102. Michail M., Birchwood M. Social anxiety disorder in first-episode psychosis: incidence, phenomenology and relationship with paranoia. Br. J. Psychiatry 2009, 195(3):234-241.
103. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65(9):732-741.
104. Morgan C., Charalambides M., Hutchinson G., Murray R.M. Migration, ethnicity, and psychosis: toward a sociodevelopmental model. Schizophr. Bull. 2010, 36(4):655-664.
105. Morrato E.H., Druss B., Hartung D.M., et al. Metabolic testing rates in 3state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch. Gen. Psychiatry 2010, 67:17-24.
106. Morrison A.P., French P., Walford L., et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br. J. Psychiatry 2004, 185:291-297.
107. Morrison P.D., Nottage J., Stone J.M., et al. Disruption of frontal theta coherence by Delta9-tetrahydrocannabinol is associated with positive psychotic symptoms. Neuropsychopharmacology 2011, 36(4):827-836.
108. Mortensen P.B., Pedersen C.B., McGrath J.J., et al. Neonatal antibodies to infectious agents and risk of bipolar disorder: a population-based case-control study. Bipolar Disord. 2011, 13(7-8):624-629.
109. Murray A., McLaughlin N.B., Bourke J.P., et al. Errors in manual measurement of QT intervals. Br. Heart J. 1994, 71:386-390.
110. Nelson B., Thompson A., Yung A.R. Basic self-disturbance predicts psychosis onset in the ultra high risk for psychosis "prodromal" population. Schizophr Bull. 2012, (Electronic publication ahead of print).
111. Newman M.E. Modularity and community structure in networks. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(23):8577-8582.
112. Nielssen O., Large M. Rates of homicide during the first episode of psychosis and after treatment: a systematic review and meta-analysis. Schizophr. Bull. 2010, 36(4):702-712.
113. Nielssen O.B., Westmore B.D., Large M.M., Hayes R.A. Homicide during psychotic illness in New South Wales between 1993 and 2002. Med. J. Aust. 2007, 186(6):301-304.
114. Nielssen O., Bourget D., Laajasalo T., et al. Homicide of strangers by people with a psychotic illness. Schizophr. Bull. 2011, 37(3):572-579.
115. O'Roak B.J., Vives L., Girirajan S., et al. Letter: sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 2012, 10.1038/nature10989. (April).
116. Pajonk F.G., Wobrock T., Gruber O., et al. Hippocampal plasticity in response to exercise in schizophrenia. Arch. Gen. Psychiatry 2010, 67(2):133-143.
117. Pang T.Y., Du X., Zajac M.S., et al. Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease. Hum. Mol. Genet. 2009, 18:753-766.
118. Patil S.T., Zhang L., Martenyi F., et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 2007, 13(9):1102-1107.
119. Pedersen C.B., Mortensen P.B. Why factors rooted in the family may solely explain the urban-rural differences in schizophrenia risk estimates. Epidemiol. Psichiatr. Soc. 2006, 15(4):247-251.
120. Penadés R., Catalán R., Puig O., et al. Executive function needs to be targeted to improve social functioning with Cognitive Remediation Therapy (CRT) in schizophrenia. Psychiatry Res. 2010, 177(1-2):41-45.
121. Perron H., Mekaoui L., Bernard C., et al. Endogenous retrovirus type W GAG and envelope protein antigenemia in serum of schizophrenic patients. Biol. Psychiatry 2008, 64(12):1019-1023.
122. Peters E.R., Williams S.L., Cooke M.A., et al. It's not what you hear, it's the way you think about it: appraisals as determinants of affect and behaviour in voice hearers. Psychol. Med. FirstView 2011, 1-8.
123. Ripke S., Sanders A.R., Kendler K.S., et al. Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 2011, 43(10):969-976.
124. Roffman J.L., Weiss A.P., Purcell S., et al. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol. Psychiatry 2008, 63(1):42-48.
125. Roffman J.L., Brohawn D.G., Nitenson A.Z., et al. Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia. Schizophr. Bull. 2011, (Electronic publication ahead of print).
126. Rosenfield P.J., Kleinhaus K., Opler M., et al. Later paternal age and sex differences in schizophrenia symptoms. Schizophr. Res. 2010, 116:191-195.
127. Scheewe, T.W., Takken, T., Kahn, R.S., et al., in press. Effects of Exercise Therapy on Cardiorespiratory Fitness in Schizophrenia Patients. Med. Sci. Sports Exerc.
128. Selten J.P., Cantor-Graae E. Social defeat: risk factor for schizophrenia?. Br. J. Psychiatry 2005, 187:101-102.
129. Silverstein M.L., Mavrolefteros G., Close D. Premorbid adjustment and neuropsychological performance in schizophrenia. Schizophr. Bull. 2002, 28:157-165.
130. Singh J., Robb A., Vijapurkar U., Nuamah I. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol. Psychiatry 2011, 70(12):1179-1187.
131. Slotema C.W., Blom J.D., de Weijer A.D., et al. Can low-frequency repetitive transcranial magnetic stimulation really relieve medication-resistant auditory verbal hallucinations? Negative results from a large randomized controlled trial. Biol. Psychiatry 2011, 69(5):450-456.
132. Smith P.J., Blumenthal J.A., Hoffman B.M., et al. Aerobic exercise and neurocognitive performance: a meta-analytic review of randomized controlled trials. Psychosom. Med. 2010, 72(3):239-252.
133. Sommer I., Witte L.D., Begemann M., Kahn R. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J. Clin. Psychiatry 2011, 73(4):414-419. (2012 Apr).
134. Sommer, I.E., Begemann, M.J., Temmerman, A., et al., in press. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr. Bull. http://dx.doi.org/10.1093/schbul/sbr004.
135. Steen R.G., Mull C., McClure R., Hamer, et al. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br. J. Psychiatry 2006, 188:510-518.
136. Stevens B., Allen N.J., Vazquez L.E., et al. The classical complement cascade mediates CNS synapse elimination. Cell 2007, 131(6):1164-1178.
137. Stokes P.R., Mehta M.A., Curran H.V., et al. Can recreational doses of THC produce significant dopamine release in the human striatum?. Neuroimage 2009, 48(1):186-190.
138. Stokes P.R., Egerton A., Watson B., et al. History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability. J. Psychopharmacol. 2012, 26(1):144-149.
139. Stone J.M., Howes O.D., Egerton A., et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol. Psychiatry 2010, 68(7):599-602.
140. Sun D., Phillips L., Velakoulis D., et al. Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals. Schizophr. Res. 2009, 108(1-3):85-92.
141. Takahashi T., Wood S.J., Yung A.R., et al. Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis. Arch. Gen. Psychiatry 2009, 66(4):366-376.
142. Turkington D., Sensky T., Scott J., et al. A randomized controlled trial of cognitive-behavior therapy for persistent symptoms in schizophrenia: a five-year follow-up. Schizophr. Res. 2008, 98(1-3):1-7.
143. Tyrka A.R., Price L.H., Marsit C., et al. Childhood adversity and epigenetic modulation of the leukocyte glucocorticoid receptor: preliminary findings in healthy adults. PLoS One 2012, 7:e30148.
144. Uhlhaas P.J., Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat. Rev. Neurosci. 2010, 11(2):100-113.
145. van Dellen A., Blakemore C., Deacon R., et al. Delaying the onset of Huntington's in mice. Nature 2000, 404:721-722.
146. van Haren N.E., Schnack H.G., Cahn W., et al. Changes in cortical thickness during the course of illness in schizophrenia. Arch. Gen. Psychiatry 2011, 68(9):871-880.
147. van Os J., Linscott R.J. Introduction: the extended psychosis phenotype-relationship with schizophrenia and with ultrahigh risk status for psychosis. Schizophr. Bull. 2012, 38(2):227-230.
148. van Os J., Linscott R.J., Myin-Germeys I., et al. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol. Med. 2009, 39(2):179-195.
149. van Os J., Kenis G., Rutten B.P.F. The environment and schizophrenia. Nature 2010, 468:203-213.
150. Vancampfort D., Probst M., Knapen J., et al. Associations between sedentary behaviour and metabolic parameters in patients with schizophrenia. Psychiatry Res. 2012, (Electronic publication ahead of print).
151. Veling W., Hoek H.W., Selten J.P., Susser E. Age at migration and future risk of psychotic disorders among immigrants in the Netherlands: a 7-year incidence study. Am. J. Psychiatry 2011, 168:1278-1285.
152. Vernon A.C., Natesan S., Modo M., Kapur S. Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol. Psychiatry 2011, 69(10):936-944.
153. Vita A., De Peri L., Silenzi C., Dieci M. Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophr. Res. 2006, 82(1):75-88.
154. Wigman J., Lin A., Vollebergh W., et al. Subclinical psychosis and depression: co-occurring phenomena that do not predict each other over time. Schizophr. Res. 2011, 130:277-281.
155. Williams H.J., Craddock N., Russo G., et al. Most genome-wide significant susceptibility loci for schizophrenia and bipolar disorder reported to date cross-traditional diagnostic boundaries. Hum. Mol. Genet. 2011, 20(2):387-391.
156. Wolf S.A., Melnik A., Kempermann G. Physical exercise increases adult neurogenesis and telomerase activity, and improves behavioral deficits in a mouse model of schizophrenia. Brain Behav. Immun. 2011, 25(5):971-980.
157. Wright I.C., Rabe-Hesketh S., Woodruff P.W., David, et al. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry 2000, 157(1):16-25.
158. Wykes T., Brammer M., Mellers J. Effects on the brain of a psychological treatment: cognitive remediation therapy. Functional magnetic resonance imaging in schizophrenia. Br. J. Psychiatry 2002, 181:144-152.
159. Yolken R. Viruses and schizophrenia: a focus on herpes simplex virus. Herpes 2004, 11(Suppl. 2):83A-88A.
160. Yolken R.H., Dickerson F.B., Fuller Torrey E. Toxoplasma and schizophrenia. Parasite Immunol. 2009, 31(11):706-715.
161. Yücel M., Solowij N., Respondek C., et al. Regional brain abnormalities associated with long-term heavy cannabis use. Arch. Gen. Psychiatry 2008, 65(6):694-701.
162. Zhang J.P., Lencz T., Malhotra A.K. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am. J. Psychiatry 2010, 167(7):763-772.
163. Zuardi A.W. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev. Bras. Psiquiatr. 2008, 30(3):271-280.
164. Zuardi A.W., Crippa J.A., Hallak J.E., et al. Cannabidiol for the treatment of psychosis in Parkinson's disease. J. Psychopharmacol. 2009, 23(8):979-983.